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ABSTRACT 
 
RNA  interference  (RNAi)  is  an  exciting  new  tool  to  effect  acute  in  vivo  knockdown  of  genes  for 
pharmacological target validation. Testing the application of this technology to metabolic disease targets, 
three RNAi delivery methods were compared in two frequently utilized preclinical models of obesity and 
diabetes, the diet-induced obese (DIO) and B6.V-Lep<ob>/J (ob/ob) mouse.  Intraperitoneal (i.p.) and high 
pressure  hydrodynamic  intravenous  (i.v.)  administration  of  naked  siRNA,  and  low  pressure  i.v. 
administration of shRNA-expressing adenovirus were assessed for both safety and gene knockdown efficacy 
using constructs targeting cJun N-terminal kinase 1 (JNK1).  Hydrodynamic delivery of siRNA lowered liver 
JNK1 protein levels 40% in DIO mice, but was accompanied by iatrogenic liver damage.  The ob/ob model 
proved even more intolerant of this technique, with hydrodynamic delivery resulting in severe liver damage 
and death of most animals. While well-tolerated, i.p. injections of siRNA in DIO mice did not result in any 
knockdown  or  phenotypic  changes  in  the  mice.  On  the  other  hand,  i.v.  injected  adenovirus  expressing 
shRNA potently reduced expression of JNK1 in vivo by 95% without liver toxicity.  In conclusion, i.p. and 
hydrodynamic injections of siRNA were ineffective and/or inappropriate for in vivo gene targeting in DIO 
and ob/ob mice, while adenovirus-mediated delivery of shRNA provided a relatively benign and effective 
method for exploring liver target silencing. 
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INTRODUCTION 
 
The advent of RNA interference (RNAi) technology has 
created new opportunities for preclinical target validation 
in murine models of disease. To maximize the potential 
utility  of  RNAi,  safe  and  effective  in  vivo  delivery 
methods  are  of  critical  importance.  A  potential 
complication  is  the  possible  impact  of  the  disease  state 
itself on the tolerability and efficacy of a particular RNAi 
delivery method. 
 
RNAi in vivo studies published to date have predominantly 
focused  on  exogenously  applied  short-interfering  (si)  or 
endogenous  short-hairpin  (sh)RNA  delivery  to  normal, 
wild-type animals or to specific regions or organs (Hannon 
and  Rossi,  2004;  Dykxhoorn  and  Lieberman,  2005; 
Shankar et al, 2005).  For liver gene knockdown, examples 
include  the  delivery  of  siRNAs  or  shRNA  expression 
constructs  to  wild-type  mice  with  the  high-pressure 
“hydrodynamic” intravenous (i.v.) tail injection technique 
(Lewis  and  Wolff,  2005)  resulting  in  protection  from 
hepatitis (Song et al, 2003), viral infection (Giladi et al, 
2003;  Tompkins  et  al,  2004)  and  tumor  progression 
(Lakka et al, 2004; Duxbury et al, 2005; Sumimoto et al, 
2005).  Successful  in  vivo  knockdown  has  also  been 
reported with a more benign intraperitoneal (i.p.) injection 
of siRNAs, although results have varied widely (Sorensen 
et  al,  2003).  Alternatively,  viral  vectors  administered  
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through low pressure, small volume i.v. tail vein injection 
have  been  reported  to  successfully  deliver  shRNA 
expression  constructs,  resulting  in  sustained  gene 
knockdown  of  liver-expressed  genes  (Xia  et  al,  2002; 
Huang et al, 2004; Lin et al, 2005). 
 
While these various methods of RNAi delivery have been 
reported  as  safe  and  effective  in  animal  models  with 
normal liver function, these methods may lose their utility 
in  animal  models  with  compromised  livers,  such  as  the 
leptin-deficient,  severely  steatotic  ob/ob  mouse  and  the 
moderately  steatotic  high  fat  diet-induced  obese  (DIO) 
mouse.  Both  of  these  models  are  used  extensively  in 
metabolic  disease  research  for  assessment  of  potential 
drug  targets,  with  many  published  examples  of  genetic 
knockouts  backcrossed  to  the  ob/ob  background  and 
knockout resistance to high fat diet-induced weight gain 
(Clee et al, 2005 ; Moraes et al, 2003; Haluzik et al, 2004).  
Acute gene knockdown through RNAi in DIO and ob/ob 
models  would  represent  a  powerful  way  to  quickly 
establish relevance for potential drug discovery targets in 
obesity, diabetes, or non-alcoholic fatty liver disease, if a 
method for well-tolerated and effective delivery could be 
established. 
 
In  the  current  study,  i.p.  injection  of  siRNA, 
hydrodynamic i.v. injection of siRNA, and (standard) i.v. 
injection of adenovirus expressing shRNA were evaluated 
in  DIO,  ob/ob,  and  normal  (lean)  control  mice.  
Observations included assessment of tolerability, degree of 
knockdown, and treatment-related physiological changes.  
Since  these  three  RNAi  delivery  methods  have  been 
reported  to  target  the  liver  (Dykxhoorn  and  Lieberman, 
2005;  Lewis  and  Wolff,  2005),  particular  attention  was 
paid to iatrogenic  hepatic effects, which could seriously 
compromise analysis and conclusions drawn for any liver-
expressed gene. With recent attention focused on cJun N-
terminal kinase 1 (JNK1) activity in the liver as a possible 
small molecule target for diabetics, we selected this gene 
for  our  pilot  si/shRNA  in  vivo  knockdown  studies.  
Previously published systemic knockout (Hirosumi et al, 
2002), inhibitory peptide (Kaneto et al, 2004; Nakatani et 
al,  2004),  and  dominant  negative  studies  (Kaneto  et  al, 
2004;  Nakatani  et  al,  2004)  were  considered  helpful 
context  for  interpretation  of  any  physiological  changes 
observed. 
 
MATERIALS AND METHODS 
 
Generation  of  synthetic  siRNAs,  vectors  expressing 
shRNAs and recombinant adenoviruses 
Two  siRNAs  for  mouse  JNK1  (Genbank  accession: 
NM_016700;  ORF  192-1346)  used  in  this  study  were 
designed  according  to  previously  described  selection 
criteria (Boese et al, 2005) and synthesized by Dharmacon, 
Inc (Boulder, CO). The siRNAs, designated siJNK1-2 and 
siJNK1-5, each consist of a 21 nucleotide (nt) long-siRNA 
duplex with a 3’-dTdT overhang. Their sequences are as 
follows: 
 
siJNK1-2 (sense/antisense):  
5’-GCAGAAGCAAACGUGACAACA-3’/ 
5’-UGUUGUCACGUUUGCUUCUGC-3’ 
siJNK1-5 (sense/antisense):  
5’-GCACACAAUAGAGGAGUGGAA-3’/ 
5’-UUCCACUCCUCUAUUGUGUGC-3’ 
 
The 21 nt non-targeting “Universal Control” siRNA used 
here is commercially available from Dharmacon (Catalog 
#: D-001220-01) and was designed to minimize targeting 
of any known human, mouse, or rat genes. Its sequence is 
as follows:   
 
Control siRNA (sense/antisense): 
5’-GGGCGUCGAUCCUAACCGG-3’/ 
5’-CCGGUUAGGAUCGACGCCC-3’ 
 
Identity  of  all  siRNAs  provided  by  Dharmacon  is 
confirmed by MALDI-TOF mass spectrometry (individual 
strand  composition)  and  non-denaturing  gel 
electrophoresis (duplex formation). 
 
To create JNK1-2 shRNA, sense and antisense sequences 
defined  by  siJNK1-2  were  separated  by  an  eight-base 
linker (TCAAGACT) to give the following sequence: 
 
5’-GCAGAAGCAAACGTGACAACATCAAGACTTGTT 
GTCACGTTTGCTTCTGC-3’ 
 
This was cloned into a pENTR
TM vector driven by a U6 
promoter (Invitrogen, Carlsbad CA). The resulting shRNA-
expressing plasmid was tested for its ability to knock down 
JNK1  protein  in  HEK293  cells  co-transfected  with  a 
vector-overexpressing mouse JNK1 cDNA (pAd/CMV/V5-
DEST;  Invitrogen,  Carlsbad,  CA)  (Yang  R  and  Wilcox 
DM,  submitted).  Knockdown  of  JNK1  protein  was 
evaluated by western blot analysis as described below. A 
second shRNA, JNK1-5 shRNA, was prepared in parallel 
based on sequences defined in siJNK1-5 but did not knock 
down  JNK1  as  effectively  as  JNK1-2  shRNA  in  vitro 
(Yang  R  and  Wilcox  DM,  submitted).  With  knockdown 
efficacy  established  for  the  JNK1-2-based  insert,  the 
targeting  construct  was  transferred  to  an  adenoviral 
pAd/BLOCK-IT
TM-DEST  vector  by  Gateway  LR 
recombination  (Invitrogen,  Carlsbad  CA).  Recombinant 
adenovirus expressing JNK 1-2 shRNA was then generated 
by  transfection  of  adenoviral-based  construct  containing 
JNK1-2  shRNA  into  HEK293  cells  as  described  in  the 
manufacturer’s  instructions  for  the  pAd/BLOCK-IT
TM 
system  (Invitrogen,  Carlsbad  CA).  Virus  destined  for  in 
vivo studies was then amplified in HEK 293 cells and then 
purified  using  cesium  chloride  gradient  centrifugation 
followed  by  gel  filtration  desalting,  following  published 
procedures  (Becker  et  al,  1994).  The  negative  control 
adenovirus  utilized  was  designed  to  express  shRNA 
specific for green fluorescent protein (GFP) and does not 
target  any  known  eukaryotic  gene.  Construct  shGFP 
(Huang et al, 2004) consisted of the following sequence: 
 
5’-GAAGCAGCACGACTTCTTCTTCAAGAGAGAAGA 
AGTCGTGCTGCTTC-3’ 
 
Animal protocols  
The Abbott Institutional Animal Care and Use Committee 
approved all protocols involving rodents in advance and 
all  studies  were  conducted  in  an  Association  for  
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Assessment and Accreditation of Laboratory Animal Care-
approved barrier facility.  All solutions to be injected were 
determined  to  be  negative  for  endotoxin  by  a  Limulus 
assay system (Cambrex, Walkersville MD). 
 
Intraperitoneal delivery study 
Male  C57Bl/6J  (Jackson  Laboratories,  Bar  Harbor  ME) 
mice were made obese by spontaneous overfeeding a high 
fat diet (D12492; 60% kcal from fat) for 20 weeks (Bush 
et  al,  2006).  Normal  (lean)  control  mice  were  fed  a 
corresponding low fat diet (D12450Bi; 10% kcal from fat).  
All  animals  were  individually  housed  in  micro-isolator 
cages for one week prior to the study for acclimation. The 
diet-induced obese (DIO) mice were assigned to treatment 
groups such that mean body weights were similar among 
groups. Mice were given daily i.p. injections with saline, 
control siRNA, or siJNK1-5 for four days (25 mg/kg, total 
volume  approximately  0.45  ml/injection).  Animals  were 
humanely euthanized by CO2 inhalation and plasma and 
liver samples collected on day five. 
 
Hydrodynamic delivery study 
Male  B6.V-Lep<ob>/J  (ob/ob)  mice  (5-6 weeks  of  age) 
purchased  from  Jackson  Laboratories (Bar  Harbor,  ME) 
were  allowed  food  (Purina  5015  Diet)  and  water  ad 
libitum.  DIO  mice  were  as  described  above  under  i.p. 
delivery methods.  For each study, mice were assigned to 
treatment groups such that mean body weights (and blood 
glucose for ob/ob) were similar among groups.  Mice were 
restrained for a single, pressurized i.v. injection of 2 ml 
saline,  control  siRNA,  siJNK1-5  or  siJNK1-2  into  the 
lateral  tail  vein  within  10  seconds  (Lewis  and  Wolff, 
2005).  Animals  were  monitored  daily  for  up  to  8  days 
following  treatment  for  adverse  effects.    Animals  were 
humanely euthanized by CO2 inhalation for end of study 
plasma and liver sample collection. 
 
Adenovirus-mediated delivery study 
Male  DIO  mice  were  assigned  to  treatment  groups  as 
above such that mean body weights were similar among 
groups. Mice were restrained for a single 100 µl lateral tail 
vein injection of either saline, 2 x 10
11 viral particles of 
adenovirus expressing nontargeting control shGFP or 2 x 
10
11  viral  particles  expressing  shRNA  targeting  JNK1 
(shJNK1-2).  Five  days  post-injection,  animals  were 
humanely euthanized by CO2 inhalation and plasma and 
liver samples were collected for analysis. 
 
Body  weight,  food  intake,  blood  chemistries  and 
histological preparation 
Body  weight  and  food  intake  were  monitored  in  each 
study. Postprandial blood glucose was assessed in all cases 
by tail snip (Precision PCx, Abbott Laboratories, Abbott 
Park,  IL).  Plasma  analyzed  for  insulin  (ALPCO 
Diagnostics,  Windham  NH)  and  alanine 
aminotransferase/aspartate  aminotransferase  (ALT/AST) 
(Sigma Diagnostics, St Louis MO) levels were measured 
according to manufacturer’s instructions from postprandial 
study samples.  Liver samples were flash frozen in liquid 
nitrogen for western blot analysis of JNK1 protein levels.  
Samples for histology were immersion fixed in 10% (v/v) 
formalin for at least 24 hr. After wet cutting, sections were 
processed and embedded in paraffin and 5-6 µm sections 
were cut and stained with hematoxylin and eosin. A single 
board  certified  pathologist  conducted  histological 
evaluation of histopathology on all studies. 
 
Western blot analysis 
Knockdown potency of JNK1 siRNA and shRNA constructs 
was initially confirmed prior to use in vivo by western blot 
analysis of cell lysates derived from either in vitro transfected 
or viral-transduced primary murine hepatocytes. Liver and fat 
tissues obtained from in vivo siRNA and shRNA treatments 
were  pulverized  and  homogenized  in  lyses  buffer  as 
previously  described  (Yang  and  Newgard,  2003).  Protein 
content of lysates was determined using a BCA assay kit (cat. 
#23227, Pierce Biologicals, Rockford IL). For western blot 
analysis,  equal  amounts  of  protein  were  loaded  onto  SDS 
gels,  electrophoresed  and  subsequently  transfered  to 
nitrocellulose membranes. The membranes were stained with 
Ponceau  S  for  15  minutes  to  confirm  equal  loading  and 
transfer  of  samples.  The  JNK  antibody  utilized  for  all 
westerns,  sc571,  was  purchased  from  Santa  Cruz 
Biotechnology  (Santa  Cruz,  CA).  Protein-antibody 
complexes were visualized using ECL plus (PerkinElmer Life 
Science,  Wellesley  MA)  following  the  manufacturer’s 
instructions, and quantitated by densitometry (GE Healthcare, 
Uppsala, Sweden).  A typical western blotting pattern with 
sc571 includes an upper band of nonspecific/unknown origin, 
and a JNK1- specific lower band. 
 
Real-time Quantitative PCR 
Viral  DNA  was  detected  in  collected  tissues  by  duplex 
real-time quantitative PCR and normalized to content of 
murine DNA. The oligonucleotide primers and probes for 
the murine and viral genes were designed using the Primer 
Express  software  program  (Applied  Biosystems, 
Framingham MA). The viral TaqMan probe was 5′ labeled 
with the reporter 6-carboxyfluorescein and 3′ labeled with 
the  quencher  tetramethylrhodamine.  The  TaqMan  probe 
for  the  murine  reference  gene  carried  a  5’-
hexachlorofluorescein  reporter  and  a  3’- 
tetramethylrhodamine quencher. 
 
Specific primers and probes for the viral E2A DBP gene 
(AP_000213): 
5′-CCAACTGCGACTTCAAGATATCG-3′ (forward) 
5′- CACAGGCTGCGCACCAT-3′ (reverse) 
5′-CGCCCGACCTGCTAAACGCG-3′ (probe) 
 
Specific  primers  and  probes  for  the  murine  Birc5  gene 
(NM_009689): 
5′-GCTGAGATAACTTGGACCTGAGTGA-3′ (forward), 
5′-GAGGCCCTGGCTGGAAAA-3′ (reverse) 
5′-TGCCACATCTAAGCCACGCATCCC-3′ (probe) 
 
The viral primers and probes were purchased from Operon 
Biotechnologies, Inc (Huntsville, AL). The murine primers 
and  probes  were  purchased  from  Integrated  DNA 
Technologies, Inc (Coralville, IA).   
 
The PCR assay was carried out at standard temperatures 
and times using the ABI AmpliTaq Gold DNA Polymerase 
Kit with Buffer II, 1.25 U polymerase and 5.5 mM MgCl2 
in 25 µl reactions.  The viral primers were used at 400 nM 
each  and  probe  at  100  nM.  The  concentrations  of  the  
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murine reference  gene  primers  and  probe  were  100  nM 
and 200 nM, respectively.  The fluorescence intensity  of 
the  reporter  labels  were  normalized  to  Texas  Red,  a 
passive reference label added to the buffer at 25 uM. PCR 
reactions  were  performed  in  an  ABI-PRISM  7900HT 
Sequence  Detection  System  (Applied  Biosystems, 
Framingham MA). Viral DNA levels were calculated by 
the relative standard curve method and were normalized to 
content of the murine gene Birc5. 
 
Statistical Analysis 
Data  are  expressed  as  the  mean  ±  S.E.M.  Statistical 
significance  was  determined  by  a  Dunnett  one-way 
ANOVA using the  statistics module  of  GraphPad  Instat 
(San Diego CA) with significance assumed at p < 0.05. 
 
RESULTS 
 
Comparison  of  siRNA  delivery  methods  in  steatotic 
murine models of diabetes and obesity 
Intraperitoneal injection of diet-induced obese (DIO) mice  
Intraperitoneal injection (i.p.) of naked siRNAs is one of 
the  most  benign  methods  reported  for  RNAi  delivery 
(Sorensen  et  al,  2003).  To  assess  the  efficacy  of  this 
method in a murine metabolic disease model, DIO mice 
were injected i.p. with 10 ml/kg (0.45 ml/mouse) daily for 
4  days  with  saline,  control  non-targeting  siRNA,  and 
siRNA  targeting  murine  JNK1  (siJNK1-5).  Previous 
studies  in  primary  hepatocytes  (Yang  et  al,  submitted) 
using  siJNK1-5  had  demonstrated  potent  knockdown  of 
JNK1  protein expression  when  transfected  in vitro.  The 
i.p.  injection  procedure  was  well  tolerated  by  the  mice, 
with no significant changes observed in food intake, body 
weight  or  plasma  glucose.  Increases  in  insulin  levels 
observed in all groups reflected values typically observed 
for daily i.p. injected animals (1.2-6.8 ng/ml,) and were 
not significantly different from vehicle vs. siRNA treated 
groups (Table 1). Liver histology appeared unchanged by 
this  regimen.  Despite  its  good  potency  as  an  in  vitro 
knockdown agent, western blot analysis of liver extracts 
revealed only minimal knockdown of hepatic JNK1 by the 
JNK1-5 siRNA construct (Figure 1A). 
 
Hydrodynamic  injections  in  diet-induced  obese  (DIO) 
mice 
To  observe  injection  method-related  effects,  DIO  and 
normal  (lean)  control  mice  were  given  a  single,  2  ml 
pressurized  tail  vein  injection  of  saline  vehicle  as 
described and reviewed (McCaffrey et al, 2002; Song et al, 
2003; Zhang et al, 2004; Dykxhoorn and Lieberman, 2005; 
Lewis  and  Wolff,  2005).  In  addition,  DIO  mice  were 
injected  with  control  non-targeting  siRNA,  or  two 
different JNK1 siRNAs (siJNK1-2 or siJNK1-5). Animals 
were observed both acutely and 5-8 days post injection.  
Both  liver  (targeted  organ)  and  adipose  tissue  (control) 
were assayed by western blot analysis using JNK antibody 
for  evidence  of  knockdown.  As  expected  (Becker  et  al, 
1994; Song et al, 2003), JNK1 levels were not diminished 
in the collected adipose samples nor in any samples from 
animals  treated  with  the  non-targeting  siRNA.  The 
siJNK1-5 mildly but significantly knocked down hepatic 
JNK1 by  40% compared to  control siRNA treated mice 
(Figure1B),  while  the  siJNK1-2  knocked  down  hepatic 
JNK1 by only 25% (data not shown).  While there were no 
 
 
 
 
Table 1. Physiological effects of JNK1 siRNA and shRNA treatment in DIO mice. Plasma glucose, insulin and ALT levels in non-
fasted ad lib-fed DIO mice five days after treatment with saline vehicle, non-targeting control virus (Control siRNA or shGFP), 
JNK1 siRNA or shRNA-expressing adenovirus (siJNK1-5, shJNK1-2).  Data represents the mean + S.E. for indicated number of 
animals in each group over five-day course of treatment.  Asterisk indicates p<0.05 vs. study control. 
 
Delivery Method  Treatment  Glucose (mg/dl)  Insulin (ng/ml)  ALT (SFU/ml) 
  saline  141.0 ± 5.74  2.27 ± 0.22   
Intraperitoneal  Control siRNA  137.2 ± 5.70  3.52 ± 0.90  ND 
n=6  siJNK1-5  140.6 ± 5.42  5.23 ± 1.36   
  saline  151.0 ± 7.71  7.11 ± 0.72  71.9 ±14.1 
Hydrodynamic  Control  siRNA  156.0 ± 7.95  7.31 ± 0.99  77.6 ± 15.3 
n=8  siJNK1-5  153.0 ± 12.72  6.09 ± 0.89  123.3 ± 18.4 
  saline  171.0 ± 5.40  1.02 ± 0.11  120.8 ± 25.2 
Ad-shRNA  Control shGFP  156.2 ± 6.02  0.72 ± 0.06  66.5 ± 11.0 
n=8  shJNK1-2  140.6 ± 1.56*  0.40 ± 0.04*  108.9 ± 19.1 
 
Note: Variation in insulin levels is common in the DIO mouse model (range 1 ng/ml -13 ng/ml), attributed to ad lib feeding as well as differential 
delivery methods and handling.  
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Figure 1. Knockdown efficiency of i.p. vs. hydrodynamic i.v. siRNA administration in DIO mice.  A. Western analysis, Ponceau S 
staining, and corresponding densitometry data for hepatic JNK1 proteins in DIO mice injected i.p with synthetic siRNA. DIO mice 
were injected daily for 4 days with 25 mg/kg with control siRNA or JNK1 targeting siRNA. Liver samples were collected on day 5, 
snap-frozen, and processed as tissue lysates (n=6). Arrow indicates JNK1 specific (lower) band. B. Western analysis, Ponceau S 
staining, and corresponding densitometry data for hepatic JNK1 protein in DIO mice treated with a single hydrodynamic injection of 
synthetic siRNA (20 mg/kg). Liver samples were collected on day 5, snap-frozen and then and processed as tissue lysates as in 1A 
(n=10). Arrow indicates JNK1 specific (lower) band.  Significant reduction in hepatic JNK1 proteins (p<0.01) indicated with 
asterisk. 
Control siRNA siJNK1
siJNK1
(lower band)
Ponceau S staining
0
0.2
0.4
0.6
0.8
1
1.2
Control siRNA siJNK1
A
r
b
i
t
r
a
r
y
 
U
n
i
t
s
Control siRNA siJNK1
siJNK1
(lower band)
Ponceau S staining
0
0.2
0.4
0.6
0.8
1
1.2
Control siRNA siJNK1
A
r
b
i
t
r
a
r
y
 
U
n
i
t
s
Ponceau S staining
0
0.2
0.4
0.6
0.8
1
1.2
Control siRNA siJNK1
A
r
b
i
t
r
a
r
y
 
U
n
i
t
s
siJNK1 Control siRNA
siJNK1
(lower band)
Ponceau S staining
0
0.2
0.4
0.6
0.8
1
1.2
Control siRNA siJNK1-5
A
r
b
i
t
r
a
r
y
 
U
n
i
t
s
*
siJNK1 Control siRNA
siJNK1
(lower band)
Ponceau S staining
0
0.2
0.4
0.6
0.8
1
1.2
Control siRNA siJNK1-5
A
r
b
i
t
r
a
r
y
 
U
n
i
t
s
*
Ponceau S staining
0
0.2
0.4
0.6
0.8
1
1.2
Control siRNA siJNK1-5
A
r
b
i
t
r
a
r
y
 
U
n
i
t
s
* 
© The Authors | Journal of RNAi and Gene Silencing | May 2007 | Vol 3, No 1 | 225-236 | OPEN ACCESS 
230 
A:              B: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C:              D: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Hydrodynamic delivery effects on blood glucose and plasma ALT/AST levels in DIO and ob/ob mice. Mice were given a 
single hydrodynamic injection of saline and monitored for glucose (mg/dl), ALT and AST (both expressed as Sigma Frankel Units or 
SFU /ml) levels at 0, 24, and 48 hr post injections (n=5). Blood glucose levels in ob/ob mice were additionally checked 1 hr post 
injection. A. Blood glucose levels and, B. plasma ALT and AST levels in DIO mice. (ALT DIO reference baseline 43-100 SFU/ml, 
AST DIO reference baseline 71-146 SFU/ml). C. Blood glucose levels (ob/ob baseline 340-425 mg/dL) and, D. plasma ALT and 
AST levels in ob/ob mice (ALT ob/ob baseline 172-295 SFU/ml; AST ob/ob baseline 152-285 SFU/ml). 4 out of 5 mice did not 
survive past 48 hr. 
 
 
acute effects on plasma glucose in these mice (Figure 2A), 
there  were  other  significant  delivery  method-associated 
tolerance issues observed.  Saline-treated DIO animals had a 
20-fold  increase  in  plasma  alanine  aminotransferase(ALT) 
levels 24 hr after injection, subsiding to 3-fold above baseline 
by 48 hr (Figure 2B). A similar pattern  of response  was 
observed  with  aspartate  aminotransferase  (AST)  (Figure 
2B). Examination of liver histology from both treated DIO 
and  control  mice  revealed  significant  hydrodynamic 
injection-related hepatic injury (Figure 3). On day 2-post 
injection,  areas  of  hemorrhage  and  peripheral 
inflammation  were  evident  in  livers  of  both  DIO  and 
control  mice  (Figure  3B  and  3F).  By  day  5,  extensive 
regions  of focal  inflammation  were  still  apparent  in  the 
DIO mice (Figure 3C), while the non-steatotic livers of the 
normal  (lean)  control  mice  appeared  to  have  largely 
recovered  (Figure  3G).  By  day  8,  the  livers  from  the 
treated  DIO  animals  had  regained  their  expected  pre-
treatment histology (Figure 3D). Measurements of insulin, 
glucose, and ALT taken on day 5 are summarized in Table 
1. Insulin levels were very high (6.09-7.31 ng/ml) across 
all  groups  5  days  post  injection,  with  no  significant 
difference  observed  for  JNK1-2  siRNA  vs.  vehicle 
treatment.  Taken  together,  these  results  indicate  that 
although  DIO  mice  can  recover  from  hydrodynamic 
injection, there are significant effects on liver function and 
histology up to 8 days post injection.  The non-steatotic 
normal control mice appear  to recover  days earlier than 
steatotic  animals,  implying  that  the  procedure  induces 
greater toxicity in animals with fatty livers (Figure 3E, 3F, 
and 3G). 
 
Hydrodynamic injections in ob/ob mice 
Given the results above with the moderately steatotic DIO 
mouse,  it  was  important  to  test  the  effects  of 
hydrodynamic  injection  in  the  severely  steatotic  ob/ob 
animal.  These mice proved to be even more sensitive to 
hydrodynamic injection than the DIO mice.  Administra- 
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tion  of  saline  vehicle  only,  utilizing  the  same  injection 
volume and pressure as in the previous DIO experiment, 
resulted in dramatic fluctuations in glucose and subsequent 
death for 4/5 treated ob/ob animals (Figure 2C). Plasma 
glucose increased from 282 mg/dl to 596 mg /dl one hour 
post injection (Figure 2C), subsequently dropping to 124 
mg/dl  (less  than  half  of  baseline  ob/ob  levels)  one  day 
post-injection.  Most mice did not survive past day 2. Both 
plasma  ALT  and  AST  levels  were  markedly  affected, 
rising one day after injection to 7000U/ml and 3800U/ml, 
respectively  (Figure  2D).    Histological  examination 
revealed extensive liver injury (Figure 4).  One hour after 
injection,  cellular  swelling  and  necrosis  were  already 
apparent (Figure 4B). By 24 hr, livers of treated animals 
exhibited  regions  of  extensive  hemorrhage  and 
inflammatory cell infiltration (Figure 4C).  Only one ob/ob 
mouse out of the five animals that received hydrodynamic 
injection survived to 3 days post treatment (Figure 4D). 
Histological  examination  of  the  single  surviving  ob/ob 
mouse  revealed  significant  hepatic  inflammation.  The 
severe response of ob/ob mice suggests that the degree of 
steatosis  is  correlated  with  the  degree  of  liver  damage 
incurred by hydrodynamic tail vein injection. 
 
Adenovirus mediated  delivery in  ob/ob and  diet-induced 
obese (DIO) mice 
Viral  expression  vectors  have  been  utilized  by  several 
investigators  to  deliver  shRNA  expression  constructs  to 
wild type mice without reports of significant injury (Xia et 
al,  2002;  Huang  et  al,  2004).  To  verify  relative  tissue 
selectivity of adenoviral-mediated shRNA delivery in DIO 
and  ob/ob  mice,  the  tissue  distribution  of  injected 
adenovirus was determined by qPCR 5 days post injection. 
Tissue  distribution  analysis  revealed  detectable  virus  in 
liver, lung (27% of liver levels), and spleen (9% of liver 
levels)  with  minimal  distribution  of  virus  found  in  the  
2.
1.
2.
1.
Figure 3. Effects of hydrodynamic injection on hepatic histology in DIO 
and control mice.  Liver sections stained with hematoxylin and eosin 
[40x] from A. untreated DIO mouse, B. DIO mouse 2 days post 
injection, C. DIO mouse 5 days post injection and D. DIO mouse 8 day 
post injection. Arrows (1) and (2) in panel C. indicate regions of necrosis 
and hemorrhage. E.  Untreated normal (lean) controls, F. Control mice 2 
days post injection and, G. Control mice 5 days post injection.  
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other organs analyzed (<1% of liver, limit  of detection) 
(Figure 5). Liver histology from shGFP-adenoviral-treated 
mice (1 x10
8 or 2 x10
8) appeared normal when analyzed 
by  H&E  staining  (Figure  6A)  and  unlike  the 
hydrodynamically-injected animals, no increases in plasma 
ALT  enzyme  levels  were  observed  in  ob/ob  mice  in 
response to treatment (Figure 6B). 
 
 
Having  established  the  adenovirus-mediated  delivery  of 
shRNA  via  normal  tail-vein  delivery  is  well-tolerated  in 
ob/ob and DIO mice, we pursued further studies with an 
shRNA construct designed to target JNK1 (shJNK1-2) as 
described in material and methods.  DIO mice were given a 
single i.v. injection of saline or 2 x 10
11 viral particles of 
adenovirus  containing  shGFP  or  adenovirus  containing 
shJNK1-2,  and  assessed  5  days  later  for  molecular  and 
metabolic changes.  Hepatic knockdown was confirmed by 
Western  blot  analysis,  and  showed  almost  complete 
silencing  (94%)  of  the  JNK1  mRNA  in  the  shJNK1-2 
treated mice, with no knockdown observed in the shGFP -
treated  mice  (Figure  7).  There  was  no  evidence  of  liver 
damage in any of the adenovirus-shRNA treated animals, 
with no changes observed in either liver histology (data not 
shown) or liver enzyme levels (Table 1). Insulin levels for 
these mice (post single tail vein injection) were much lower 
(0.4-1.02 ng/ml) than that observed in the previous 5 day 
i.p.  injected  and  hydrodynamic-treated  animals.  Lack  of 
overt  toxicity  and  potent  knockdown  of  hepatic  JNK1 
enabled  preliminary  targeting  construct-specific  effects  to 
be observed: A 10% reduction in blood glucose levels, and a 
45% decrease in plasma insulin levels (Table 1). 
DISCUSSION 
 
The  application  of  RNAi  to  new  therapeutic  target 
discovery and validation is nothing short of revolutionary.  
While  the  use  of  RNAi  for  screens  and  in  vitro  target 
validation has been very successful and is in widespread 
use, application of RNAi to in vivo target validation has 
been a more difficult challenge. In order to utilize this new 
technology to characterize and validate potential obesity 
and  diabetes  drug  targets,  it  is  essential  to  establish 
methodology  that  would  be  both  efficacious  for  gene 
knockdown and safe in the murine disease models used for 
metabolic  disease  studies,  including  the  ob/ob  and  DIO 
mouse. 
 
Repeated  i.p.  injections  of  anti-sense  oligonucleotides 
have been used successfully in various animal models for 
gene  knockdown  studies  (Zinker  et  al,  2002;  Yu  et  al, 
2005), although phenotypic  changes have typically  been 
reported after multiple (3 to 6 weeks) weeks of treatment.  
This  injection  method  appears  to  be  well  tolerated  by 
steatotic  animal  models  like  DIO  and  ob/ob  mice.  
Following  a  5-day  regimen  reported  with  anti-sense 
oligonucleotide (ASO) treatment in which protein levels of 
PTP1B were significantly reduced (Zinker et al, 2002), we 
chose a comparable short course of four consecutive days 
of i.p. dosing for naked siRNA administration. No hepatic 
JNK1  knockdown  was  observed.    Therefore,  although 
well-tolerated  and  safe,  a  short  i.p.  injection  course  of 
naked siRNA was ineffective for siRNA delivery in our 
hands.  Recent successes have been reported using direct 
administration of cholesterol-coupled siRNAs  (Soutschek  
Figure 4. Effects of hydrodynamic injection on hepatic histology 
in ob/ob mice.  Liver sections stained with hematoxylin and eosin 
in ob/ob mice A. untreated [40x], B. 1 hour post injection [100x], 
C. one day post injection [20x], and D. 3 days post injection 
(single surviving ob/ob mouse out of five treated [100x]). 
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Figure 5. Tissue distribution analysis of detectable virus in DIO mice.  qPCR analysis of adenoviral tissue distribution in DIO mice 5 
days post injection.  Liver virus load was set at one for comparison to other tissues.  
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Figure 6. Effects of adenoviral mediated injections on hepatic histology and ALT levels 5 days post injection. A. Liver sections 
stained with hematoxylin and eosin in ob/ob mice [40x] and, B. DIO mice [100x] C. Plasma ALT levels in ob/ob mice injected with 
four different batches of control adenovirus expressing shRNA for GFP at either 2 x 108 or 1 x 109 viral particles/mouse (n=5). 
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Figure 7. Hepatic JNK1 protein levels 5 days post injection of adenovirus-expressing JNK1 shRNA.  Western analysis and 
corresponding densitometry analysis for hepatic JNK1 proteins in DIO mice treated with vehicle, or 2 x 1011 viral particles control 
shRNA (shGFP), or JNK1 shRNA (shJNK1).  Data represent the mean + S.E. for eight animals in each group. Significant 
knockdown (p= 0.0001) is indicated by asterisk in shJNK1 treated group.  Arrow indicates JNK1 specific (lower) band. 
 
 
 
et  al,  2004).  We  have  not  investigated  these  carriers  in 
detail, however, as they are not without toxicities and were 
considered  potentially  problematic  with  our  steatotic 
animal models (Sorensen et al, 2003). 
 
The  hydrodynamic  or  high  pressure  tail  vein  injection 
technique (Liu et al, 1999; Lewis and Wolff, 2005) has 
been  the  most  commonly  used  technique  for  siRNA 
delivery.  Injected volumes of fluid corresponding to up to 
10% of total body weight are injected over 5-10 seconds, 
disrupting inter-hepatocyte tight junctions and facilitating 
siRNA  uptake  (Zhang  et  al,  2004).  High  incidence  of 
cardiac  events  reported  in  hydrodynamic-injected  mice 
(Zhang et al, 2004; Zhang et al, 2004) may be due to the 
addition of a 2 ml fluid volume into an approximately 2.5 
ml circulating blood volume over a short period of time.  
Hydrodynamic tail vein injection has been apparently used 
successfully in mouse models with normal liver function, 
however, consistent with our findings, these reports also 
indicate  transient  increases  in  ALT/AST  levels  and 
evidence of liver damage 2 days post injection (Liu et al, 
1999;  Zhang,  1999;  Lewis  and  Wolff,  2005).  Here  we 
have shown that two of the steatotic mouse models used 
most widely in diabetes and obesity research, the DIO and 
ob/ob,  are  very  sensitive  to  this  technique.    DIO  mice 
receiving  hydrodynamic  treatment  suffered  extensive, 
differentially  reversible  liver  damage  accompanied  by 
ALT/AST  spikes  24  hr  post  treatment.  Histological 
examination  of  livers  at  varying  times  post  injection 
revealed extensive hemorrhage and necrosis after two days 
that  appeared  to  be  resolving  by  day  5  and  virtually 
normalized  by  day  8.    In  contrast, lean  control animals 
with normal livers showed initial hepatic injury on day 2 
but this appeared to be fully resolved by day 5. In the more 
extensively  steatotic  ob/ob  mouse,  hydrodynamic 
injections resulted in lethal complications. Blood glucose 
levels increased one hour after the injection and then fell 
well  below  baseline.  Many  of  treated  ob/ob  died 
immediately following injection, and most did not survive 
3 days post-injection.  Liver damage in the ob/ob animals 
was more extensive than that observed in the DIO mice, 
possibly  indicating  delayed  or  reduced  hepatic  repair 
capabilities. The degree of injury and differential recovery 
rate  between  normal  controls,  moderately  steatotic  DIO 
and  severely  steatotic  ob/ob  mice,  may  suggest  that  the 
successful  hydrodynamic  injection  reported  in  the 
literature (Giladi et al, 2003; Song et al, 2003; Tompkins 
et al, 2004) are due to the ability of normal animals, with 
healthy  livers,  to  recover  from  the  hepatic  insult  that 
occurs post-injection.   
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In  the  DIO  mice  studies  reported  here,  hydrodynamic 
injection-derived liver damage prevented any conclusions 
regarding JNK1 knockdown-related effects. Such delivery-
related side effects would be particularly problematic with 
novel,  less  well-characterized  targets.  Therefore, 
hydrodynamic  injection  of  siRNA  should  be  considered 
unsuitable for in vivo target validation using the DIO and 
ob/ob  mouse  models.  Given  these  findings,  it  may  be 
important  to  consider  background  liver  damage/repair 
even in the interpretation of hydrodynamic injection-based 
studies  in  normal  animals.  Depending  on  experimental 
time-line or the target being manipulated, contribution to 
overall phenotype could be substantial. 
 
For target validation studies, a viable alternative to i.p. 
and  hydrodynamic  siRNA  delivery  methods  is 
adenovirus-mediated  shRNA  delivery.  Adenoviral 
shRNA  expression  constructs  continuously  express 
shRNA, allowing for sustained knockdown for up to two 
weeks  (Xu  et  al,  2005;  Yamazaki  et  al,  2005), 
advantageous  for  eliciting  physiological  change  and 
modeling  small  molecule  activity.  Adenovirus  is 
particularly  attractive  for  in  vivo  studies  due  to  its 
episomal,  non-integrating  mode  of  expression  and 
typically  high  titer.  Immune  response  to  adenovirus 
challenge  is  well-documented  and  cannot  be  entirely 
avoided, but properly controlled studies limited to the 5 
to  14  day  response time-frame can  allow dissection  of 
viral-mediated  vs.  gene  knockdown-mediated  changes.  
Tissue distribution analysis by qPCR carried out 5 days 
post tail  vein injection indicated that the liver was the 
major site of viral deposition, with some virus detected in 
the  lung  and  spleen  (27%  and  9%  of  liver  levels, 
respectively). Given these findings, shRNA delivery via 
adenovirus  seemed  particularly  appropriate  for  short-
term validation studies of liver-expressed targets. 
 
In  contrast  to  the  hepatotoxic  responses  seen  with 
hydrodynamic injection, no evidence of histological liver 
damage or overt stress was observed in either adenovirus-
shRNA treated DIO or ob/ob animals.  Animals appeared 
healthy when monitored for up to 14 days post-injection.  
Knockdown  efficacy  was  also  achieved,  with  JNK1 
protein  levels  reduced  in  the  DIO  mice  by  94%  when 
assayed five days post-injection. Recently, other studies of 
ours  utilizing  adenovirus-mediated  delivery  of  shRNA 
have  shown  equivalent  knockdown  efficacy  achieved  in 
ob/ob  mice  for  other  liver-expressed  targets  (Xu  et  al, 
2005; Xu et al, 2006). 
 
In  the  absence  of  delivery  method-associated  effects, 
physiological  changes  observed  could  be  preliminarily 
attributed to the JNK1-targeting construct. In DIO mice, 
plasma insulin was reduced 45% and non-fasting glucose 
was  reduced  by  10%  in  shJNK1-2  treated  animals 
compared  to  the  non-targeting  shRNA-treated  controls. 
Confirmation  of  the  effects  of  JNK1  knockdown  via 
shRNA  will  await  follow-up  studies  with  additional 
knockdown positive constructs/viruses. 
 
Identification  of  safe  and  efficacious  delivery  methods 
that  will  allow  siRNA  or  shRNA  to  be  applied  either 
systemically  or  directly  to  target  organs  remains  a 
significant  hurdle  for  both  preclinical  and  clinical 
applications of RNAi.  In order to apply this approach to 
in  vivo  target  validation,  disease  model-specific 
responses need to be assessed and accommodated. In this 
study, the steatotic livers of ob/ob and DIO mice were 
particularly  sensitive  to  the  otherwise  widely  reported 
hydrodynamic  tail  vein  injection  technique.  Hepatic 
damage resulting from injection eliminated this method 
as  a  viable  approach  for  validating  liver  expressed 
diabetes  and  obesity  targets.    In  contrast,  adenoviral-
delivered  shRNA  allowed  effective  knockdown  in  the 
absence  of  hepatic  damage  in  these  mouse  models, 
enabling  the  observation  and  measurement  of  target-
specific findings. While direct treatment of siRNA would 
obviate potential complications with viral infection and 
provide  an  opportunity  to  utilize  chemically  modified 
controls, a suitable delivery method has  yet to become 
widely available. Of the currently available alternatives, 
viral  delivery  of  shRNA  provides  optimal  gene 
knockdown  with  minimal  side  effects,  permitting 
conclusive target validation studies to be conducted with 
novel targets for diabetes and obesity. 
 
CONCLUSIONS 
 
• Delivery  of  naked  siRNA  by  i.p.  injection  was  well-
tolerated,  but  resulted  in  insufficient  target  gene 
knockdown when tested in DIO mice. 
 
• Although modestly effective at target gene knockdown, 
hydrodynamic delivery of siRNA resulted in severe liver 
damage compromising any interpretation of study results 
in  DIO  and  ob/ob  mice.    Degree  of  damage  was 
correlated with the degree of steatosis in the two models. 
 
• Adenoviral  vector  delivery  of  JNK1  shRNA  via  tail 
vein  injection  resulted  in  effective  target  gene 
knockdown and no overt toxicities in DIO mice.  This 
RNAi delivery method also proved to be well-tolerated 
in  control  experiments  with  ob/ob  mice,  making  this 
mode of RNAi delivery the method of choice for target 
validation studies in these two models of diabetes and 
obesity.  
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LIST OF ABBREVIATIONS  
 
DIO; diet induced obese 
i.p.; intraperitoneal 
i.v.; intravenous 
ALT; alanine aminotransferase 
 si; short-interfering 
sh; short-hairpin 
JNK1; cJun N-termal kinase 
Ad; adenovirus 
GFP; green fluorescence protein 
AST; aspartate aminotransferase 
qPCR; quantitative poymerase chain reaction 
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